Silan Ventures
Investments in the Land of Milk and (Date) Honey
A family office backing Israeli seed and A-round technology companies, and the founders building them.
The opportunity
Israel’s A Round is among the cheapest asset classes in the world
Hundreds of new Israeli technology companies are founded every year, yet the venture landscape in Israel remains underserved compared with California. Promising A Round companies that might price at $20M to $50M pre-money in Silicon Valley gladly take a steep discount, $2M to $12M pre-money, to work with an ecosystem that brings distribution, not just capital.
Partners including IBM, EY, Citi and Microsoft filter that annual pipeline and surface the strongest companies. From those, we run deep diligence on up to 25 ventures a year. Read our full story.
Recent Milestones
Acquisitions, listings and financings across the portfolio since 2021.
- 2026YonalinkAcquired by Veeva Systems
- 2026CyabraListed on Nasdaq (CYAB) through a SPAC merger
- 2026Bucket ListersMajority stake acquired by MARI, the Ari Emanuel and Mark Shapiro company
- 2026DataRailsRaised a $70M Series C led by One Peak
- 2025Titan PharmaceuticalsMerged with Black Titan Corporation (Nasdaq: BTTC)
- 2025Leo AIRaised $9.7M to build AI for mechanical engineering
- 2024StackStateAcquired by SUSE and folded into Rancher Prime
- 2023SynergioSymrise took a minority stake, with an option to majority control
- 2022Arena PharmaceuticalsAcquired by Pfizer for $6.7 billion
- 2022Alpha Tau MedicalListed on Nasdaq (DRTS) through a SPAC merger
- 2021ImVisionAcquired by Intuit
Strategic Partners
Corporate and institutional relationships that source deal flow and open distribution channels across the U.S., Europe and Asia.
Exits
40+ successful exits from 150+ angel and very early public investments worldwide, with what became of each company.
Visit Yonalink
Visit Bucket Listers
Visit Titan Pharmaceuticals
View archived Colors AI website from 2026 on the Wayback Machine
View archived Arena Pharmaceuticals website from 2022 on the Wayback Machine
Visit Alpha Tau Medical
Visit On Track Innovations
View archived ImVision AI website from 2022 on the Wayback Machine
Visit Cognigo
Visit TopTix
Visit Enzymotec
Visit Blink Charging
Visit Zoomd
Visit M-Systems
Visit AnswerThink
Visit Stratasys
Visit Narus
Visit Bolt
Visit Clearium
Visit Cleveland BioLabs
Visit Concentric
Visit SIGA Technologies
Visit XTL Bio
Visit ArrayComm
Visit Unimed Pharma
Visit Cambridge Heart
Visit EasyPark
Visit Boston Life Sciences
Visit NOMOS
Visit Wave Systems
Visit Wave IP
Visit TigApo
Visit iSuppli
Visit Third Wave Technologies
Visit Gadline
Current Portfolio
Israeli and U.S. technology companies we back today, across cyber security, medical devices, AI, fintech and energy.
Frequently Asked
What stage does Silan Ventures invest in?
Silan Ventures invests at Seed and A Round, typically at $2M to $12M pre-money valuations. Companies at a comparable stage in Silicon Valley often price at $20M to $50M pre-money.
Where does Silan Ventures invest?
Primarily in Israeli technology companies, alongside Silicon Valley investments. Our family office has made 85+ investments in Israel since 1992.
What is the track record?
40+ successful exits from 150+ angel and very early public investments worldwide, across more than three decades of Israeli and Silicon Valley investing.
Which sectors does Silan Ventures cover?
Our portfolio and exits span cyber security, medical devices and diagnostics, biopharma, artificial intelligence, fintech, adtech, IoT, energy and enterprise software.
How does Silan Ventures select companies?
Hundreds of new Israeli tech companies are founded each year. Partners including IBM, EY, Citi and Microsoft surface the strongest of them. Silan Ventures and its strategic advisors then run deep diligence on up to 25 ventures annually.
How can a startup get in touch?
Use the contact form on this site. We read every submission and respond to companies that fit our stage and sector focus.